Answers are grounded in this paper and cite their sources.
VDC-1101 has activity against canine CTCL and could provide another treatment option in a disease process with a poor prognosis.
No takes yet. Share an insight, caveat, or question.
Morges et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: